Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
56
XENE Quote, Financials, Valuation and Earnings
Last price:
$42.23
Seasonality move
:
1.72%
Day range:
$41.44 - $43.18
52-week range:
$26.74 - $46.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
443.80x
P/B ratio:
5.83x
Volume:
735.3K
Avg. volume:
879.5K
1-year change:
7.24%
Market cap:
$3.3B
Revenue:
--
EPS (TTM):
-$3.88
Analysts' Opinion
-
Consensus RatingXenon Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 16 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $55.87, Xenon Pharmaceuticals, Inc. has an estimated upside of 32.3% from its current price of $42.23.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $44.00 representing 100% downside risk from its current price of $42.23.
Fair Value
-
According to the consensus of 16 analysts, Xenon Pharmaceuticals, Inc. has 32.3% upside to fair value with a price target of $55.87 per share.
XENE vs. S&P 500
-
Over the past 5 trading days, Xenon Pharmaceuticals, Inc. has overperformed the S&P 500 by 0.39% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Xenon Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Xenon Pharmaceuticals, Inc. revenues have been falling on a year-over-year basis for 6 quarters in a row. In the most recent quarter Xenon Pharmaceuticals, Inc. reported revenues of --.
Earnings Growth
-
Xenon Pharmaceuticals, Inc. earnings have been falling on a year-over-year basis for 6 quarters in a row. In the most recent quarter Xenon Pharmaceuticals, Inc. reported earnings per share of -$1.15.
Enterprise value:
2.8B
EV / Invested capital:
--
Price / LTM sales:
443.80x
EV / EBIT:
--
EV / Revenue:
374.58x
PEG ratio (5yr expected):
-0.28x
EV / Free cash flow:
-11.10x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$4.9M
Return On Assets:
-38.99%
Net Income Margin (TTM):
-4084.45%
Return On Equity:
-44.39%
Return On Invested Capital:
-43.83%
Operating Margin:
-969.84%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | $7.5M | -- | -- | |
| Gross Profit | -$3.2M | -$2.7M | $4.9M | -$669K | -$641K | |
| Operating Income | -$203.7M | -$255.5M | -$340.8M | -$73.7M | -$96.3M | |
| EBITDA | -$200.5M | -$252.8M | -$338.2M | -$73M | -$95.7M | |
| Diluted EPS | -$2.66 | -$2.81 | -$3.88 | -$0.81 | -$1.15 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $256.3M | $649.2M | $531M | $659.6M | $480.1M | |
| Total Assets | $264.4M | $775.8M | $671.1M | $835.9M | $607.8M | |
| Current Liabilities | $12.9M | $15.5M | $24.7M | $29.7M | $38.3M | |
| Total Liabilities | $15.4M | $22.7M | $34.5M | $38.1M | $48.3M | |
| Total Equity | $248.9M | $753.1M | $636.6M | $797.8M | $559.5M | |
| Total Debt | $2.6M | $7.2M | $9.8M | $8.4M | $6.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$140.2M | -$161.7M | -$251.8M | -$51.2M | -$72.5M | |
| Cash From Investing | $115.9M | -$171.5M | $253.1M | $2.2M | $38.8M | |
| Cash From Financing | $23.1M | $320.7M | $15.5M | -- | $2.4M | |
| Free Cash Flow | -$147.4M | -$164M | -$253M | -$51.8M | -$72.8M | |
XENE
Sector
Market Cap
$3.3B
$25.5M
Price % of 52-Week High
90.62%
49.47%
Dividend Yield
0%
0%
Shareholder Yield
-0.49%
-1.77%
1-Year Price Total Return
7.24%
-21.96%
Beta (5-Year)
0.957
0.499
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$42.25
200-day SMA
Buy
Level
$37.80
Bollinger Bands (100)
Buy
Level
40.09 - 43.63
Chaikin Money Flow
Buy
Level
561.8K
20-day SMA
Buy
Level
$41.90
Relative Strength Index (RSI14)
Buy
Level
51.12
ADX Line
Buy
Level
13.85
Williams %R
Neutral
Level
-42.5816
50-day SMA
Sell
Level
$42.49
MACD (12, 26)
Buy
Level
8.00
25-day Aroon Oscillator
Buy
Level
20
On Balance Volume
Neutral
Level
763.5K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.3877)
Buy
CA Score
(Annual)
Level (-0.1984)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (0.3997)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.
Stock Forecast FAQ
In the current month, XENE has received 16 Buy ratings 0 Hold ratings, and 0 Sell ratings. The XENE average analyst price target in the past 3 months is $55.87.
-
Where Will Xenon Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Xenon Pharmaceuticals, Inc. share price will rise to $55.87 per share over the next 12 months.
-
What Do Analysts Say About Xenon Pharmaceuticals, Inc.?
Analysts are divided on their view about Xenon Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Xenon Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $44.00.
-
What Is Xenon Pharmaceuticals, Inc.'s Price Target?
The price target for Xenon Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $55.87 according to 16 Wall Street analysts, 16 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is XENE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Xenon Pharmaceuticals, Inc. is a Buy. 16 of 16 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of XENE?
You can purchase shares of Xenon Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Xenon Pharmaceuticals, Inc. shares.
-
What Is The Xenon Pharmaceuticals, Inc. Share Price Today?
Xenon Pharmaceuticals, Inc. was last trading at $42.23 per share. This represents the most recent stock quote for Xenon Pharmaceuticals, Inc.. Yesterday, Xenon Pharmaceuticals, Inc. closed at $42.23 per share.
-
How To Buy Xenon Pharmaceuticals, Inc. Stock Online?
In order to purchase Xenon Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get XENE Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
XENE
Sector
P/E ratio
--
23.41x
PEG ratio
-0.28x
-0.01x
P/B ratio
5.83x
1.78x
Price / LTM sales
443.80x
1.56x
Growth Metrics
XENE
Sector
Revenue growth
--
3.51%
Earnings growth
-42.34%
9.95%
Revenue (5-year growth)
-100%
6.45%
Earnings forecast
-$1.18
-$0.19
Profitability
XENE
Sector
Profitability FY 2024
-$2.6M
$2.6M
Return on invested capital
-43.83%
-33.25%
Return on assets
-38.99%
-29.68%
Return on equity
-44.39%
-38.71%
Earnings Date
Last Earnings Date
Nov
3
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
2
Balance Sheet
XENE
Sector
Total cash
$462.3M
$25M
Short term investments
$484.2M
$24M
Total assets
$1.1B
$71.9M
Long term debt
$6.8M
$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 21
RingCentral, Inc. [RNG] is up 34.37% over the past day.
Sell
9
FROG alert for Feb 21
JFrog Ltd. [FROG] is down 24.98% over the past day.
Buy
72
SNSE alert for Feb 21
Sensei Biotherapeutics, Inc. [SNSE] is up 23.81% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
